413 related articles for article (PubMed ID: 28197805)
1. Economic Analysis and Budget Impact of Tenofovir and Entecavir in the First-Line Treatment of Hepatitis B Virus in Italy.
Ruggeri M; Basile M; Coretti S; Drago C; Cicchetti A
Appl Health Econ Health Policy; 2017 Aug; 15(4):479-490. PubMed ID: 28197805
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis between entecavir and lamivudine for the treatment of chronic hepatitis B in Hong Kong.
Lee KK; Wu DB; Chow PY; Lee VW; Li H
J Gastroenterol Hepatol; 2012 Jul; 27(7):1167-74. PubMed ID: 22141402
[TBL] [Abstract][Full Text] [Related]
3. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
[TBL] [Abstract][Full Text] [Related]
5. Entecavir for the treatment of chronic hepatitis B infection.
Shepherd J; Gospodarevskaya E; Frampton G; Cooper K
Health Technol Assess; 2009 Oct; 13 Suppl 3():31-6. PubMed ID: 19846026
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
7. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program.
Yuan Y; Iloeje U; Li H; Hay J; Yao GB
Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Yuan Y; Iloeje UH; Hay J; Saab S
J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
[TBL] [Abstract][Full Text] [Related]
9. [Cost-Fffectiveness of Two Antiviral Therapies for Chronic Hepatitis B in Peru: Entecavir and Tenofovir].
Bolaños-Díaz R; Tejada RA; Sanabria C; Escobedo-Palza S
Rev Peru Med Exp Salud Publica; 2017; 34(3):377-385. PubMed ID: 29267761
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Dakin H; Sherman M; Fung S; Fidler C; Bentley A
Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China.
Toy M; Hutton DW; So SK
PLoS One; 2015; 10(11):e0139876. PubMed ID: 26536626
[TBL] [Abstract][Full Text] [Related]
13. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
Buti M; Brosa M; Casado MA; Rueda M; Esteban R
J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.
Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA
Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Alternative Antiviral Strategies for the Treatment of HBeAg-Positive and HBeAg-Negative Chronic Hepatitis B in the United Kingdom.
Bermingham SL; Hughes R; Fenu E; Sawyer LM; Boxall E; T Kennedy P; Dusheiko G; Hill-Cawthorne G; Thomas H
Value Health; 2015 Sep; 18(6):800-9. PubMed ID: 26409607
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
Dakin H; Bentley A; Dusheiko G
Value Health; 2010 Dec; 13(8):922-33. PubMed ID: 20825619
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
[TBL] [Abstract][Full Text] [Related]
19. Should chronic hepatitis B be treated as early as possible?
Hulstaert F; Schwierz C; Nevens F; Thiry N; Gamil M; Colle I; Van de Sande S; Horsmans Y
Int J Technol Assess Health Care; 2013 Jan; 29(1):35-41. PubMed ID: 23298548
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil.
Costa AM; L 'italien G; Nita ME; Araujo ES
Braz J Infect Dis; 2008 Oct; 12(5):368-73. PubMed ID: 19219274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
